BioLineRx Announces Expansion of Immuno-Oncology Collaboration in Pancreatic Cancer

x30-50 patients in additional arm will be investigated under the collaboration. Results from combination of BL-8040 and KEYTRUDA® (pembrolizumab) in COMBAT/KEYNOTE-202 study will be reported in H2 2018 as planned.